Hospital das Clínicas da Universidade Federal de Goiás - UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050

Select an option

I am a doctor

I am a sponsor

Our team

Medical staff

Rodrigo Sebba Aires

Open studies

Cardiovascular disease

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - Amgen

Obesity

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - Amgen

Anemia

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia - LUMINA 3 - Sanofi

Cholangitis

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis - VANTAGE - Mirum Pharmaceuticals, Inc.

Crohn's disease

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease - AMAY - Eli Lilly and Company

Elevated Lipoprotein A

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company

Heart failure

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation - HERMES - Novo Nordisk A/S

Hemolytic Disease

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) - AZALEA - Janssen Research & Development, LLC

Inflammation

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation - HERMES - Novo Nordisk A/S

Multiple Sclerosis

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis - FREXALT - Sanofi

Myeloproliferative syndromes

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis - PACIFICA - Swedish Orphan Biovitrum

Non-Hodgkin Lymphoma

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma - GOLSEEK-1 - Celgene

Rare diseases

The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease - LIBRA - Sanofi

Renal disease

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads

Hospital das Clínicas da Universidade Federal de Goiás - UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050

Select an option

I am a doctor

I am a sponsor

Our team

Medical staff

Rodrigo Sebba Aires

Open studies

Cardiovascular disease

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - Amgen

Obesity

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - Amgen

Anemia

Cholangitis

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis - VANTAGE - Mirum Pharmaceuticals, Inc.

Crohn's disease

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease - AMAY - Eli Lilly and Company

Elevated Lipoprotein A

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company

Heart failure

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation - HERMES - Novo Nordisk A/S

Hemolytic Disease

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) - AZALEA - Janssen Research & Development, LLC

Inflammation

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation - HERMES - Novo Nordisk A/S

Multiple Sclerosis

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis - FREXALT - Sanofi

Myeloproliferative syndromes

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis - PACIFICA - Swedish Orphan Biovitrum

Non-Hodgkin Lymphoma

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma - GOLSEEK-1 - Celgene

Rare diseases

The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease - LIBRA - Sanofi

Renal disease

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads